Main Street Financial Solutions LLC Invests $3.82 Million in Zoetis Inc. $ZTS

Main Street Financial Solutions LLC acquired a new position in Zoetis Inc. (NYSE:ZTS) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 53,144 shares of the company’s stock, valued at approximately $3,819,000.

Other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in Zoetis by 12.9% during the fourth quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock worth $6,011,802,000 after purchasing an additional 5,474,210 shares during the period. BlackRock Inc. raised its position in shares of Zoetis by 10.8% in the second quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock valued at $2,833,453,000 after purchasing an additional 3,845,869 shares during the period. J. Stern & Co. LLP raised its position in shares of Zoetis by 12,431.2% in the fourth quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock valued at $3,028,423,000 after purchasing an additional 23,877,416 shares during the period. State Street Corp lifted its stake in shares of Zoetis by 0.8% during the 4th quarter. State Street Corp now owns 19,796,891 shares of the company’s stock valued at $2,490,845,000 after buying an additional 149,382 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Zoetis by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 11,327,679 shares of the company’s stock worth $1,420,294,000 after buying an additional 189,235 shares during the period. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Price Performance

Shares of NYSE ZTS opened at $74.04 on Wednesday. The stock’s 50-day simple moving average is $76.01 and its two-hundred day simple moving average is $98.13. Zoetis Inc. has a twelve month low of $71.00 and a twelve month high of $160.48. The firm has a market capitalization of $30.60 billion, a P/E ratio of 12.20, a P/E/G ratio of 1.28 and a beta of 0.73. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The firm had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. During the same quarter last year, the company posted $1.76 EPS. The company’s revenue for the quarter was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, equities analysts anticipate that Zoetis Inc. will post 6.2 EPS for the current fiscal year.

Analyst Ratings Changes

ZTS has been the subject of a number of recent research reports. Weiss Ratings lowered shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, June 12th. JPMorgan Chase & Co. dropped their target price on Zoetis from $130.00 to $115.00 and set an “overweight” rating on the stock in a research report on Friday, August 7th. Barclays cut their price target on Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a report on Wednesday, July 1st. Zacks Research cut Zoetis from a “hold” rating to a “strong sell” rating in a research report on Monday, August 10th. Finally, Argus reiterated a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. Eight research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $109.62.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.